Experimental mRNA vaccine targets Tough-to-Treat cancers in first human trial
NCT ID NCT07100210
Summary
This early-stage trial is testing a new mRNA vaccine approach for people with advanced solid tumors that have stopped responding to standard treatments. The study will first check if the treatment is safe and tolerable in a small group of patients. Researchers will also look for early signs that the vaccine might help control tumor growth in cancers like advanced soft tissue sarcoma, head and neck cancer, and melanoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.